{
}
UBS has reiterated its Buy recommendation for Novartis, maintaining a target price of 111 E, indicating a potential upside of 16%. Following strong Q4 2024 results, sales and core EBIT forecasts for 2025-29 have been increased by approximately 3% annually. Novartis anticipates mid- to high-single-digit sales growth and high-single- to low-double-digit growth in core operating income for 2025.
UBS has reiterated its Buy recommendation for Novartis, maintaining a target price of €111, indicating a 16% upside potential. Following strong Q4 2024 results, UBS has increased sales and core EBIT projections for 2025-29 by approximately 3% annually, anticipating mid- to high-single-digit sales growth and high- to low-single-digit core EBIT growth for 2025.
UBS has reiterated its Buy recommendation for Novartis, maintaining a target price of €111, indicating a potential upside of 16%. Following strong Q4 2024 results, UBS has increased sales and core EBIT forecasts for 2025-29 by approximately 3% annually. Novartis anticipates mid- to high-single-digit sales growth and high-single- to low-double-digit growth in core operating income for 2025.
UBS has reiterated its recommendation on Novartis stock, as reported by Cercle Finance and published by BOURSORAMA. The analysis is provided for informational purposes only, with BOURSORAMA disclaiming any responsibility for its content and ensuring no conflicts of interest affect its objectivity.
UBS has maintained its 'Buy' rating for Novartis, setting a price target of 111 Swiss francs. Analyst Matthew Weston has adjusted his estimates following the company's strong quarterly results released on Monday.
UBS has rated NOVARTIS AG as a 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential total loss of capital, and expert investment advice is recommended. No liability for the accuracy or completeness of the information is assumed, and the content reflects the views of individual authors rather than wallstreetONLINE.
UBS has maintained its "Buy" rating for Novartis, setting a price target of 111 francs. Analyst Matthew Weston highlighted the company's strong results in a recent study published on January 31, 2025.
Novartis AG, a leading global pharmaceutical company, generates sales primarily from oncology (29.9%), immunology (17.2%), and cardiovascular, renal, and metabolic diseases (14.1%). The company operates 33 production sites worldwide, with sales distributed across Europe (33%), the USA (39.5%), Asia-Africa-Australasia (20.5%), and Canada and Latin America (7%).
Goldman Sachs maintains a "Neutral" rating for Novartis with a target price of 100 francs, anticipating solid performance this year. Berenberg rates it "Hold" at 86 francs, while Bernstein Research is more optimistic with an "Outperform" rating and a target of 115 francs. However, Novartis faces legal challenges in the U.S. related to bribery allegations, contributing to a 6.43% drop in share value last month, currently trading at EUR 94.29.
UBS has maintained a "Buy" rating for Novartis, setting a price target of 111 francs, following the company's strong performance results. Analyst Matthew Weston highlighted the positive outcomes in a report published on January 31, 2025.
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Novartis receives buy recommendation with growth expectations for 2025
12:23 03.02.2025
ubs maintains buy rating on novartis with target price of 111 euros
12:19 03.02.2025
ubs maintains buy rating on novartis with target price of 111 euros
12:16 03.02.2025
ubs maintains positive outlook on novartis stock analysis released
12:16 03.02.2025
ubs maintains buy rating for novartis with target of 111 francs
11:50 03.02.2025
ubs rates novartis ag as buy with investment risks highlighted
11:37 31.01.2025
ubs maintains buy rating for novartis with price target of 111 francs
11:37 31.01.2025
novartis ag maintains strong global presence with diverse pharmaceutical portfolio
11:27 31.01.2025
novartis faces legal challenges as analysts issue mixed ratings
Euro
Novartis AG
Raiffeisen Bank International AG
USA
CHN
James Quigley
Florent Cespedes
Luisa Hector
Show more
10:53 31.01.2025
ubs maintains buy rating for novartis with price target of 111 francs
10:37 31.01.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Central Bank Actions
Retail and Consumer Goods
CEO Changes
GDP Growth & Recession Forecasts
Global Trade Developments
Financial Scams and Security
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Market Analysis and Predictions
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Domestic Politics
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
End Federal Reserve USD
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
Vietnamese Đồng
People: